phrykt

ArriVent BioPharma, Inc. (AVBP): who owns it and who trades it

As of Nov 16, 2026, AVBP insiders reported 1 open-market sale worth $13M and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Hhlr Advisors, Ltd. (10% owner), with $13M. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling ArriVent BioPharma

From the latest filings

Overall: more selling than buying. Insiders and famous investors mostly sold. Funds mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns AVBP

158 funds and institutions reported AVBP shares worth $1.6B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Montanova Capital, LLC with 10.2%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

Montanova Capital, LLC10.2%
Infinitum Asset Management, LLC10.0%
Hhlr Advisors, Ltd.8.9%
BlackRock, Inc.7.4%
Orbimed Advisors LLC6.8%
FMR LLC (Fidelity)6.3%
Octagon Capital Advisors LP4.5%
Vanguard Capital Management LLC4.0%
Sofinnova Investments, Inc.3.8%
State Street Corp3.8%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Montanova Capital, LLC4.52M10.22%$157M+3%
Infinitum Asset Management, LLC4.44M10.04%$154M+7%
Hhlr Advisors, Ltd.3.93M8.89%$136MNo change
BlackRock, Inc.3.25M7.35%$113M+28%
Orbimed Advisors LLC3.03M6.85%$105MNo change
FMR LLC (Fidelity)2.78M6.29%$96.5M-8%
Octagon Capital Advisors LP1.97M4.46%$68.5MNo change
Vanguard Capital Management LLC1.77M4.02%$61.7M+16%
Sofinnova Investments, Inc.1.70M3.84%$58.9MNo change
State Street Corp1.69M3.83%$58.8M+19%
Vivo Capital, LLC1.68M3.81%$58.4M+90%
Novo Holdings A/s1.50M3.39%$52.1M-23%
General Catalyst Group Management, LLC1.49M3.38%$51.9MNo change
Logos Global Management LP1.00M2.26%$34.7M+186%
Geode Capital Management, LLC972,6262.20%$33.8M+21%
California State Teachers Retirement System930,9632.11%$26.8M+4707%
D. E. Shaw & Co., Inc.872,0111.97%$30.3M+136%
Goldman Sachs Group Inc853,7231.93%$29.7MNo change
HSG Holding Ltd663,3081.50%$23MNo change
Point72 Asset Management, L.P.566,7961.28%$19.7M-24%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, AVBP insiders reported $0 of open-market purchases and $13M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$13M
1 trades, 1 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Dec 10, 2025
Filed Feb 3, 2026

Purchases and sales by month

$13M$13MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Dec 10, 2025Hhlr Advisors, Ltd. +110% ownerSale555,555$23.37$13MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Hhlr Advisors, Ltd.10% owner–$13MDec 10, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

AVBP short interest

High short interest. 11.8% of AVBP shares are sold short: about 1 share in 9. Over the last 12 reports the number of shares short went down 21%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 5.80M AVBP shares were sold short, 11.8% of the shares outstanding, down 14.8% from the report before. At the average daily volume of 1.69M shares, buying them all back would take about 3.4 trading days (days to cover).

Shares short, % of all shares

11.8%May 15Oct 3019.2%

Days to cover

3.4May 15Oct 3025.6

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20265.80M11.76%-15%1.69M3.4
Oct 15, 20266.81M13.80%-19%3.05M2.2
Sep 30, 20268.45M17.14%-4%751,30211.2
Sep 15, 20268.77M17.78%+1%495,48917.7
Aug 31, 20268.69M17.63%+6%425,43320.4
Aug 14, 20268.23M16.69%+2%378,01521.8
Jul 31, 20268.05M18.20%+5%578,05913.9
Jul 15, 20267.67M17.34%+1%429,47817.9
Jun 30, 20267.62M17.25%-3%842,8319.1
Jun 15, 20267.85M17.75%+2%598,35913.1
May 29, 20267.71M17.44%+6%534,53114.4
May 15, 20267.30M16.51%+3%323,71622.6

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

ArriVent BioPharma company events

ArriVent BioPharma filed 11 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 9, 2026.

  1. Nov 9, 2026LeadershipStuart Lutzker, M.D., Ph.D. notified the Company of his intention to retire from the position of President, Research and Development of the Company and as a director of the Company, effective as of December 1, 2026. Filing
  2. Oct 26, 2026AnnouncementThe information set forth in the press release referred to in Item 7.01 above, other than the second paragraph thereof, is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K. Item 9.01 Financial Statements and Exhibits. Filing
  3. Oct 19, 2026AnnouncementShared information with investors. Filing
  4. Oct 13, 2026AnnouncementThe information set forth in the press release referred to in Item 7.01 above, other than the second and third paragraphs thereof, is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K. Item 9.01 Financial Statements and Exhibits. Filing
  5. Oct 6, 2026AnnouncementThe information set forth in the press release referred to in Item 7.01 above, other than the second paragraph thereof, is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K. Item 9.01 Financial Statements and Exhibits. Filing
  6. Aug 12, 2026AgreementArriVent BioPharma, Inc. entered into a Collaboration and License Agreement with Shanghai Allist Pharmaceuticals Co., Ltd., a pharmaceutical company incorporated under the laws of China. Filing
  7. Jun 22, 2026VoteReported shareholder vote results. Filing
  8. May 11, 2026AnnouncementArriVent BioPharma, Inc. filed with the Securities and Exchange Commission a prospectus supplement, dated May 11, 2026, with respect to the Company’s existing “at the market offering” program. Filing
  9. May 11, 2026ResultsReleased financial results. Filing
  10. Mar 17, 2026AnnouncementThe information set forth in the press release referred to in Item 7.01 above, other than the second paragraph thereof, is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K. ​ Item 9.01 Financial Statements and Exhibits. ​ (d) Exhibits. ​ Exhibit No. ​ ​ Description… Filing
  11. Mar 5, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

ArriVent BioPharma financials

Famous investors that hold AVBP

4 of the 50 well-known investors we track reported holding AVBP in their latest 13F filing. The largest position is Israel Englander's, worth $15.4M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 2026508,511$15.4M0.0%+16%
Steve Cohen · Point72 Asset ManagementQ3 2026493,205$14.9M0.0%-13%
Ken Griffin · Citadel AdvisorsQ3 202630,623$927K0.0%-80%
Paul Tudor Jones · Tudor Investment CorpQ3 202615,654$474K0.0%-33%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named AVBP in the last 120 days.

FiledHolderFormStake
Nov 5, 2026FMR LLC13G/A5.8%
Nov 5, 2026FMR LLC13G/A5.8%
Oct 13, 2026Vivo Opportunity Fund Holdings, L.P.13G3.1%
Oct 13, 2026Vivo Opportunity Fund Holdings, L.P.13G3.1%
Oct 8, 2026ORBIMED ADVISORS LLC13D/A5.8%
Oct 8, 2026ORBIMED ADVISORS LLC13D/A5.8%

Questions about ArriVent BioPharma, Inc. (AVBP) stock

Who owns the most AVBP stock?

The largest reported owner of ArriVent BioPharma, Inc. (AVBP) is Montanova Capital, LLC, with 10.2% of the company. In total, 158 funds and institutions reported holding AVBP at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are AVBP insiders buying or selling?

In the last 12 months, AVBP insiders reported no open-market purchases and 1 sale worth $13M. The latest trade was on Dec 10, 2025. See every trade.

What is the short interest in AVBP?

As of Oct 30, 2026, 5.80M AVBP shares were sold short, 11.8% of the shares outstanding, down 14.8% from the report before. At the average daily volume of 1.69M shares, buying them all back would take about 3.4 trading days (days to cover). See the history.

Which famous investors hold AVBP?

4 of the 50 well-known investors we track reported AVBP in their latest 13F filing, including Israel Englander, Steve Cohen, Ken Griffin. The largest position is worth $15.4M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.